16th - 17th May 2025 3rd SCN2A & SCN8A

scientific conference & family gathering

scientific lead: Walid Fazeli (Bonn/Germany) and Elena Gardella (Dianalund/Denmark)

Conference program

BROUGHT TO YOU BY:







FILADELFIA



www.scn2a.de www.scn8a.eu w

www.scn2a-italia.it

\bigcirc

Location

Kranz Parkhotel in Siegburg/Bonn - Germany www.kranzparkhotel.de Booking under: info@kranzparkhotel.de Booking code: EU Conference

Registration



Registration is free of charge and includes catering during the conference, as well as dinner on Friday.

https://lets-meet.org/reg/b7f4598e20ab473313



Support - travel grants

We are pleased to announce that we will cover 70,00€ per participant per night (up to a maximum of 3 nights).

For additional travel grants, please send your inquiry to info@scn2a.de.

ŶŶŶ

Child care

We offer non-medical child care during conference hours at the hotel. This service is available for both affected children and their siblings.

Please register separately at: https://www.leo-kinderevents.de/scn2a

Programm

3rd SCN2A & SCN8A Scientific Conference and Family Gathering

Siegburg/Bonn (Germany) (16th - 17th May 2025)

THURSDAY, May 15th 2025

Time	Subject	Speaker
18:00 - 19:00	Welcoming of participants	

FRIDAY, May 16th 2025

Time	Subject	Speaker		
08:00 - 09:00	Registration of participants			
09:00 - 09:15	Welcome and Introduction	Walid Fazeli (Bonn) Elena Gardella (Dianalund) Patient advocacy groups		
1st session (Chairs: Markus Wolff/ Patient advocacy groups) CLINICAL SPECTRUM				
09:15 - 09:35	Precision medicine in DEEs - current status	Ingrid Scheffer (Melbourne)		
09:35 – 09:50	SCN8A – clinical spectrum	Elena Gardella (Dianalund)		
09:50 - 10:05	SCN2A – clinical spectrum	Katherine Howell (Melbourne)		
DISEASE MECHANISMS				
10:05 - 10:25	Genetic mechanisms of sodium-channelopathies	Rikke Møller (Dianalund)		
10:25 - 10:45	Targeting aberrant dendritic integration to treat cognitive comorbidities of epilepsy	Heinz Beck (Bonn)		
Coffee break (10:45 – 11:15)				
2nd session (Chairs: Elena Gardella/ Patient advocacy groups) BEYOND SEIZURES				
11:15-11:35	Movement disorders in childhood and adolescents	Anne Koy (Cologne)		
11:35 – 11:45	Movement disorders in SCN2A	Vanessa Kasto (Bonn) Walid Fazeli (Bonn)		
11:45 – 11:55	A joined wearable and video analysis data approach to phenotype people with SCN2A and SCN8A	Sunanjay Bajaj (Houston) Dennis Lal (Houston)		
11:55 – 12:05	Episodic ataxia in SCN2A	Sopio Gverdtsiteli (Dianalund) Walid Fazeli (Bonn)		
12:05 - 12:20	Analysis of over 30,000 phenotypic annotations in individuals with SCN8A-related disorders	Ingo Helbig (Philadelphia)		
Lunch break (12:20 – 13:30)				

3rd session (Chairs: Walid Fazeli/ Patient advocacy groups) TREATMENT				
13:30 - 13:40	SCN8A: anti-seizure medication	Elena Gardella + Team (Dianalund)		
13:40 - 13:50	SCN2A: anti-seizure medication	Beattie Goad (Melbourne) Daniel Fritzen (Bonn)		
13:50 - 14:05	Partial allele-specific knockout by CRISPR rescues Scn8a DEE mice	Wenxi Yu (Michigan)		
14:05 - 14:20	Gene therapy approaches for the treatment of SCN8A DEE	Manoj Patel (Virginia)		
14:20 - 14:35	The Regulatory Landscape of DEE Clinical Trials: - to basket or not?	Orrin Devinsky (New York)		
Industry session				
14:35 - 14:55	Update on Stoke Therapeutic's Investigational Therapy for Dravet Syndrome	Stoke Therapeutics (Brian Werneburg)		
14:55 – 15:15	Update in drug development for DEEs	Praxis Precision Medicine		
15:15 – 15:30	Bexicaserin in DEEs	t.b.c.		
	Coffee break (15:30 - 16:15)			
4th session (Chairs: Rikke Møller/ Patient advocacy groups) SHORT COMMUNICATIONS				
16:15 – 16:25	Improving parental classification of seizures and seizure-like events in children with SCN2A/8A DEEs	Orrin Devinsky (New York)		
16:25 – 16:35	Development of clinical and genetic inclusion criteria for high risk disease modifying therapies in SCN2A	Tobias Brünger (Houston) Dennis Lal (Houston)		
16:35 - 16:45	Sleep disturbances in SCN2A	Sarah Krämer (Bonn)		
16:45 – 16:55	Sleep disturbances in SCN8A	Francesca Furia (Dianalund)		
16:55 – 17:05	MRI findings in SCN2A	Daniel Bamborschke (Bonn)		
17:05 – 17:15	Functional characterization of SCN8A variants and pharmacological response: Insights for precision medicine	Anthony Frosio (Milan)		
17:15 – 17:25	Prediction tools reliability in SCN8A-related disorders	Francesca Furia (Dianalund) Roberto Previtali (Dianalund)		
17:25 – 17:35	NDEEMA across sodium channelopathies	Sopio Gverdtsiteli (Dianalund)		
17:35 - 17:45	Cenobamate in sodium channelopathies	Marina Trivisano (Rome)		
End of Day 1				

SATURDAY, May 17th 2025

Time	Subject	Speaker		
09:00 – 09:05	Introduction	Walid Fazeli (Bonn) Elena Gardella (Dianalund) Patient advocacy groups		
1st session (Chairs: Katherine Howell/ Patient advocacy groups) SUMMARY DAY 1				
09:05 - 09:20	SCN2A	Walid Fazeli (Bonn)		
09:20 - 09:35	SCN8A	Elena Gardella (Dianalund)		
09:35 - 10:00	Discussion on Day 1			
PALLIATIVE CARE				
10:00 - 10:20	Empowering Caregivers: Perspective on supporting medically complex children	Kacie Craig (The Cute Syndrome Foundation)		
10:20 - 10:45	Pediatric palliative care	Martin Staudt (Munich)		
10:45 – 11:00	Discussion on both talks			
	Coffee break (11:00 – 11:30)			
2nd session (Chairs: Walid Fazeli/ Patient advocacy groups) MISCELLANEOUS				
11:30 - 11:50	Detail-oriented visual processing and reduced perception of global patterns in the <i>Scn2a</i> ^{+/-} rat model of autism spectrum disorder	Angelina Tadic (Trieste)		
11:50 - 12:15	Parental mosaicism in DEEs - implications for families	Elisabeth Mangold (Bonn)		
12:15 – 12:45	QoL and Burden of illness in SCN2A- and SCN8A-associated disorders	Adam Strzelczyk (Frankfurt) Elena Gardella (Dianalund) Walid Fazeli (Bonn)		
	Lunch break (12:45 – 14:00)			
	3rd session (Chairs: Elena Gardella/ Patient adv PATIENT ADVOCACY GROUPS	ocacy groups)		
14:00 - 14:15	How can PAOs grow and strengthen their capacity to support research? Opportunities through philanthropic foundations	SCN2A Germany		
14:15 – 14:30	Connections that count: partnering with professionals at every stage of the journey	Leah Schust Myers (SCN2A Family Foundation)		
14:30 - 14:45	Building scientific advocacy through collaboration with other DEEs and rare diseases	Luismi Aras (SCN8A Spain)		
14:45 - 15:00	Concluding remarks	Walid Fazeli (Bonn) Elena Gardella (Dianalund) Patient advocacy groups		
End of the conference				

Supported by grants from:

Chan Zuckerberg Initiative 😚



Sponsored by:

Platinum Sponsor:



Silver Sponsors:







www.scn2a.de www.scn8a.eu www.scn2a-italia.it